PT - JOURNAL ARTICLE AU - Wan-Ting Hsu AU - Lorenzo Porta AU - Tzu-Chun Hsu AU - Shyr-Chyr Chen AU - Chien-Chang Lee TI - Association between use of aspirin use before hospital admission and sepsis outcomes: a population-based cohort study AID - 10.1101/2020.06.09.20126938 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.09.20126938 4099 - http://medrxiv.org/content/early/2020/06/11/2020.06.09.20126938.short 4100 - http://medrxiv.org/content/early/2020/06/11/2020.06.09.20126938.full AB - Objectives Antiplatelet agents have been shown to reduce serum levels of inflammatory markers and may reduce sepsis mortality. A previous randomized clinical trial did not find that aspirin use after hospitalization, compared with placebo, improve acute respiratory distress syndrome within 7 days. We aimed to examine the association between preadmission use of aspirin and sepsis outcome.Methods We conducted a population-based cohort study based on the National Health Insurance Research Database of Taiwan. The association between aspirin use and 90-day mortality in sepsis patients was determined by Cox proportional hazard models, adjusting for either individual covariates or a propensity score. Restricted mean survival time (RMST) analysis was performed as a sensitivity analysis.Results Of 52,982 patients with sepsis, 12,776 received preadmission use of aspirin, while 39,081 did not receive any antiplatelets. Use of aspirin before sepsis admission was associated with a decreased risk of 90-day mortality (PS-adjusted HR: 0.89, 95% CI: 0.84-0.93). RMST analysis confirmed the beneficial effect of aspirin which was associated with a 2% increase in survival time (RMST ratio 1.02, 95% CI: 1.01-1.03), when compared to nonuse. On PS adjusted analysis, the odds ratios (OR) of respiratory failure with the preadmission use of aspirin was 0.98 (95% CI: 0.93-1.03), but we did not find any significant association between prior aspirin use and respiratory failure.Conclusions Our study confirms that prehospital aspirin use was associated with a reduced 90-day mortality rate among sepsis patients, but we did not find any substantial association with respiratory or acute renal failure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Taiwan Ministry of Science and Technology Grants, MOST 105-2811-B-002-031. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board of the National Taiwan University Hospital. Informed consents from patients were not required because all the patients were anonymous.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data were generated at National Taiwan University Health Data Research Center. The derived data that support the findings of this study are available from the corresponding author on reasonable request.